Medicinal Chemistry Research Group, Research Center for Natural Sciences Magyar tudósok krt. 2, Budapest, H-1117, Hungary.
Medicinal Chemistry Research Group, Research Center for Natural Sciences Magyar tudósok krt. 2, Budapest, H-1117, Hungary; Division of Medicinal Chemistry, Faculty of Sciences, Amsterdam Institute for Molecules, Medicines and Systems (AIMMS), Vrije Universiteit Amsterdam, De Boelelaan 1108, Amsterdam, 1081 HZ, Netherlands.
Bioorg Chem. 2021 Jun;111:104832. doi: 10.1016/j.bioorg.2021.104832. Epub 2021 Mar 19.
In addition to the orthosteric binding pocket (OBP) of GPCRs, recent structural studies have revealed that there are several allosteric sites available for pharmacological intervention. The secondary binding pocket (SBP) of aminergic GPCRs is located in the extracellular vestibule of these receptors, and it has been suggested to be a potential selectivity pocket for bitopic ligands. Here, we applied a virtual screening protocol based on fragment docking to the SBP of the orthosteric ligand-receptor complex. This strategy was employed for a number of aminergic receptors. First, we designed dopamine D preferring bitopic compounds from a D selective orthosteric ligand. Next, we designed 5-HT selective bitopic compounds starting from the 5-HT preferring ergoline core of LSD. Comparing the serotonergic profiles of the new derivatives to that of LSD, we found that these derivatives became significantly biased towards the desired 5-HT receptor target. Finally, addressing the known limitations of H antihistamines, our protocol was successfully used to eliminate the well-known side effects related to the muscarinic M activity of amitriptyline while preserving H potency in some of the designed bitopic compounds. These applications highlight the usefulness of our new virtual screening protocol and offer a powerful strategy towards bitopic GPCR ligands with designed receptor profiles.
除了 GPCR 的正位结合口袋(OBP),最近的结构研究表明,还有几个变构位点可供药理学干预。胺能 GPCR 的次级结合口袋(SBP)位于这些受体的细胞外前庭,它被认为是双位点配体的潜在选择性口袋。在这里,我们应用了一种基于片段对接的虚拟筛选方案到正位配体-受体复合物的 SBP。该策略已应用于多种胺能受体。首先,我们从 D 选择性正位配体设计了多巴胺 D 偏好的双位点化合物。接下来,我们从 LSD 中 5-HT 优先的麦角灵核心开始设计 5-HT 选择性的双位点化合物。将新衍生物的血清素特性与 LSD 进行比较,我们发现这些衍生物显著偏向于所需的 5-HT 受体靶标。最后,针对 H 抗组胺药的已知局限性,我们的方案成功地用于消除与阿米替林的毒蕈碱 M 活性相关的已知副作用,同时在一些设计的双位点化合物中保留 H 效力。这些应用突出了我们新的虚拟筛选方案的有用性,并为具有设计受体特征的双位点 GPCR 配体提供了一种强大的策略。